Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...

AI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...

Alphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. ...

Rep. Eric Burlison is demanding answers from the FBI regarding the suspicious deaths and disappearances of at least 13 American scientists ...

Anthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...

The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, ⁠the company ⁠said on M...

Swiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal...

The Delhi High Court has stepped in with a firm hand, criticizing the patent office for its sluggish response to Novartis AG's 2011 patent ...

Natco filed writ petition citing procedural irregularities and violation of principles of natural justice by the Assistant Controller of Pa...

The settlement of the lawsuit was announced by Acting Manhattan U.S. Attorney Audrey Strauss, who said the company splurged on "speaking fe...

The Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic...

According to the judgment, Cipla had claimed that 10 tablets of Onbrez cost Rs 677 as opposed to its own drug priced at Rs 130.

Cipla was making submission for lifting the stay ordered by a single judge bench restraining it from manufacturing the drug.

"We will not give you an interim order. We will hear it on an early date and dispose it of. Notice. Renotify on February 5," the bench said.

Novartis may face penalties in India for submitting 'fake' document to the Drug Controller General of India (DCGI) for a veterinary medicin...

Stockists had complained that Novartis' sales representatives had been offering massive discounts in order to push sales.

Novartis has been selling it at international prices all over the world and whatever price it sells in the US, it sells at the same price i...